IndustryCompany release

Abeona buys Ellodi's EoE drug ABO-801 for $20M in stock and lines up $30M private placement

🇺🇸 Abeona Therapeutics Inc. (ABEO) · Mon 09 Nov 2026

On November 9, 2026, Abeona Therapeutics announced it acquired APT-1011, renamed ABO-801, from Ellodi Pharmaceuticals. ABO-801 is a once-daily oral fluticasone propionate tablet for eosinophilic esophagitis with FDA Orphan Drug designation. The deal involves no upfront cash, and Abeona also signed a $30 million private placement; it plans to start a new Phase 3 study in Q2 2027, after two earlier Phase 3 studies missed their co-primary symptom endpoint.

Company's press release (SEC filing): Abeona Therapeutics Inc. ↗

Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →